Home » Stocks » BPTH

Bio-Path Holdings, Inc. (BPTH)

Stock Price: $5.58 USD -0.31 (-5.26%)
Updated Apr 16, 2021 4:00 PM EDT - Market closed
Market Cap 38.77M
Revenue (ttm) n/a
Net Income (ttm) -10.88M
Shares Out 6.95M
EPS (ttm) -2.83
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day April 16
Last Price $5.58
Previous Close $5.89
Change ($) -0.31
Change (%) -5.26%
Day's Open 5.90
Day's Range 5.51 - 5.93
Day's Volume 294,039
52-Week Range 3.12 - 24.34

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), Bio-Path Holdings, Inc. (NASDAQ: BPTH) and Cidara Therapeutics, Inc. (NASDAQ: CDTX) are among the early movers in the biotech space. ACADIA Wilts On FDA Rejec...

Other stocks mentioned: ACAD, CDTX
1 week ago - Benzinga

Bio-Path Holdings Inc (NASDAQ: BPTH) has completed the safety run-in of Stage 2 of the Phase 2 study evaluating prexigebersen to treat acute myeloid leukemia (AML) in combination with frontline therapie...

1 week ago - Benzinga

HOUSTON, April 05, 2021 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a port...

1 week ago - GlobeNewsWire

Bio-Path (BPTH) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

1 month ago - Zacks Investment Research

HOUSTON, March 11, 2021 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ: BPTH), a biotechnology company leveraging its proprietary DNAbilize™ liposomal delivery and antisense technology to develop ...

1 month ago - GlobeNewsWire

Conference Call to be Held Today at 8:30 A.M. ET Conference Call to be Held Today at 8:30 A.M. ET

1 month ago - GlobeNewsWire

HOUSTON, March 03, 2021 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ: BPTH) a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a port...

1 month ago - GlobeNewsWire

HOUSTON, Feb. 18, 2021 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (Nasdaq:BPTH), a biotechnology company leveraging its proprietary DNAbilize® liposomal delivery and antisense technology to develop a ...

2 months ago - GlobeNewsWire

HOUSTON, Feb. 16, 2021 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (Nasdaq:BPTH), a biotechnology company leveraging its proprietary DNAbilize® liposomal delivery and antisense technology to develop a ...

2 months ago - GlobeNewsWire

HOUSTON, Feb. 13, 2021 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (Nasdaq:BPTH), a biotechnology company leveraging its proprietary DNAbilize® liposomal delivery and antisense technology to develop a ...

2 months ago - GlobeNewsWire

Bio-Path (NASDAQ: BPTH) shares are trading higher Wednesday after the company announced it received a third U.S. patent grant related to the manufacture of its platform technology. Bio-Path Holdings Inc...

2 months ago - Benzinga

Bio-Path Holdings (BPTH) stock is rocketing higher on Wednesday after announcing patent updates for its DNAbilize platform. The post BPTH Stock: Why Bio-Path Holdings Is Skyrocketing 200% Today appeared...

2 months ago - InvestorPlace

Provides Expanded Protection to Seminal Patents Related to DNAbilize Provides Expanded Protection to Seminal Patents Related to DNAbilize

2 months ago - GlobeNewsWire

Trial to Evaluate Ability of BP1002, Targeting Bcl-2 Protein, to Treat Refractory/Relapsed Lymphoma and Chronic Lymphocytic Leukemia Patients Trial to Evaluate Ability of BP1002, Targeting Bcl-2 Protein...

4 months ago - GlobeNewsWire

Bio-Path Holdings' (BPTH) CEO Peter Nielsen on Q3 2020 Results - Earnings Call Transcript

Other stocks mentioned: NLSN
5 months ago - Seeking Alpha

Conference Call to be Held Today at 8:30 A.M. ET Conference Call to be Held Today at 8:30 A.M. ET

5 months ago - GlobeNewsWire

HOUSTON, Nov. 06, 2020 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ: BPTH), a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a port...

5 months ago - GlobeNewsWire

BPTH stock received a boost on Thursday after Bio-Path received a notice of allowance for a strategic patent for its candidate Prexigebersen. The post Bio-Path Holdings News: Why BPTH Stock Is Soaring T...

5 months ago - InvestorPlace

Growing Patent Estate Creates Value and Supports Key Combination Therapies Growing Patent Estate Creates Value and Supports Key Combination Therapies

5 months ago - GlobeNewsWire

HOUSTON, Sept. 09, 2020 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ: BPTH), a biotechnology company leveraging its proprietary DNAbilize™ liposomal delivery and antisense technology to develo...

7 months ago - GlobeNewsWire

Bio-Path (BPTH) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

7 months ago - Zacks Investment Research

Bio-Path Holdings Inc (BPTH) CEO Peter Nielsen on Q2 2020 Results - Earnings Call Transcript

8 months ago - Seeking Alpha

Conference Call to be Held Today at 8:30 A.M. ET Conference Call to be Held Today at 8:30 A.M. ET

8 months ago - GlobeNewsWire

Combination of Prexigebersen, Decitabine and Venetoclax Is Expected to Have Several Potential Pathways to Registration Combination of Prexigebersen, Decitabine and Venetoclax Is Expected to Have Several...

8 months ago - GlobeNewsWire

HOUSTON, Aug. 07, 2020 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ: BPTH), a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a po...

8 months ago - GlobeNewsWire

Bio-Path Holdings, Inc. (BPTH) CEO Peter Nielsen on Q1 2020 Results - Earnings Call Transcript

Other stocks mentioned: NLSN
11 months ago - Seeking Alpha

Conference Call to be Held Today at 8:30 A.M. ET Conference Call to be Held Today at 8:30 A.M. ET

11 months ago - GlobeNewsWire

To say the least, Bio-Path Holdings Inc. (NASDAQ: BPTH) stock has taken a beating in the past five years.

1 year ago - 24/7 Wall Street

On Friday, March 6, oncology drug development company Bio-Path Holdings Inc. (NASDAQ: BPTH) reported fiscal year 2019 results.

1 year ago - 24/7 Wall Street

HOUSTON, March 11, 2020 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a po...

1 year ago - GlobeNewsWire

What is it like to have a stock plunge 90% in less than a year and wipe out a huge amount of market capitalization?

1 year ago - 24/7 Wall Street

Tap five stocks with increasing P/E ratios to try an out-of-the-box approach.

Other stocks mentioned: DENN, HEI, NVEE, OMP
1 year ago - Zacks Investment Research

HOUSTON, Jan. 08, 2020 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ: BPTH), a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a po...

1 year ago - GlobeNewsWire

Bio-Path (BPTH) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

1 year ago - Zacks Investment Research

Combination of Prexigebersen and Decitabine Showed Encouraging Safety and Efficacy Results Combination of Prexigebersen and Decitabine Showed Encouraging Safety and Efficacy Results

1 year ago - GlobeNewsWire

HOUSTON, Nov. 25, 2019 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (Nasdaq:BPTH), a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a por...

1 year ago - GlobeNewsWire

HOUSTON, Nov. 21, 2019 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (Nasdaq:BPTH), a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a por...

1 year ago - GlobeNewsWire

Phase 1 Clinical Trial to Evaluate Ability of BP1002, Targeting Bcl-2 Protein, to Treat Refractory/Relapsed Lymphoma and Chronic Lymphocytic Leukemia Patients Phase 1 Clinical Trial to Evaluate Ability ...

1 year ago - GlobeNewsWire

Bio-Path (BTPH) earnings for the biotechnology company's third quarter of 2019 saw BTPH stock taking a wild ride on Friday.

1 year ago - InvestorPlace

Bio-Path Holdings, Inc (BPTH) CEO Peter Nielsen on Q3 2019 Results - Earnings Call Transcript

1 year ago - Seeking Alpha

Brings 25 Years of Experience in Business Development and Marketing Brings 25 Years of Experience in Business Development and Marketing

1 year ago - GlobeNewsWire

HOUSTON, Sept. 03, 2019 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ: BPTH), a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a p...

1 year ago - GlobeNewsWire

HOUSTON, Aug. 26, 2019 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a por...

1 year ago - GlobeNewsWire

Bio-Path Holdings, Inc. (BPTH) CEO Peter Nielsen on Q1 2019 Results - Earnings Call Transcript

1 year ago - Seeking Alpha

Bio-Path rocketed Monday after withdrawing its December offering for stocks and warrants. Bio-Path is working on a number of cancer treatments.

2 years ago - Investors Business Daily

Bio-Path Holdings Inc.'s stock rocketed 48% in morning trade Monday, after the biotechnology company focused on cancer treatments filed to withdraw a common stock offering.

2 years ago - Market Watch

Bio-Path Holdings (BPTH) CEO, Peter Nielsen on Q4 2018 Results - Earnings Call Transcript

2 years ago - Seeking Alpha

Bio-Path Holdings Inc. (NASDAQ: BPTH) shares are on a rampage, with its second day of more than doubling. Shares actually were halted at multiple points during the day for volatility spikes.

2 years ago - 24/7 Wall Street

Bio-Path Holdings Inc (BPTH) shares are on a tear, advancing over 160 percent on roughly 37 times their average volume Wednesday and trading up more than 200 percent Thursday afternoon.

2 years ago - Benzinga

About BPTH

Bio-Path Holdings, Inc. operates as a clinical and preclinical stage oncology focused RNAi nano particle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction. Its lead drug candidate is prexigebersen, which is in Phase II clinical trials for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome. The company is also d... [Read more...]

Industry
Biotechnology
Founded
2007
Stock Exchange
NASDAQ
Ticker Symbol
BPTH
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to one analyst, the rating for BPTH stock is "Buy" and the 12-month stock price forecast is 12.50.

Price Target
$12.50
Analyst Consensus: Buy